Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity

Vaccine

Volumn 18, Issue 15, 2000, Pages 1473-1484

  Dilts, D A ^a   Riesenfeld Orn I ^a   Fulginiti, J P ^a   Ekwall, E ^b   Granert, C ^b   Nonenmacher, J ^a   Brey, R N ^a   Cryz, S J ^c   Karlsson, K ^b   Bergman, K ^b   Thompson, T ^a   Hu, B ^a   Bruckner A H ^a   Lindberg, A A ^a  

^a PFIZER INC   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Berna Biotech AG   (Switzerland)

Author keywords

Clinical trial; S. typhi; Vaccine

Indexed keywords

TYPHOID VACCINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SALMONELLA TYPHI; SEROCONVERSION; TYPHOID FEVER;

ADOLESCENT; ADULT; BACTERIAL VACCINES; CELL CYCLE PROTEINS; FREEZE DRYING; HEAT-SHOCK PROTEINS; HUMANS; MIDDLE AGED; OSMOLAR CONCENTRATION; PERIPLASMIC PROTEINS; SALMONELLA TYPHI; SERINE ENDOPEPTIDASES; VACCINATION; VACCINES, ATTENUATED;

EID: 0033985811     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00424-7     Document Type: Conference Paper

References (29)

1. Germanier R., Fürer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131:1975;553-558.
2. Tacket C.O., Hone D.M., Curtiss I.R., Kelly S.M., Losonsky G., Guers L., Harris A.M., Edelman R., Levine M.M. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:1992;536-541.
3. Hone D.M., Harris A.M., Chatfield S., Dougan G., Levine M.M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 9:1991;810-816.
4. Hohmann E.L., Oletta C.A., Killeen K.P., Miller S.I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1996;1408-1414.
5. Levine M.M., Ferreccio C., Cryz S., Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 336:1990;891-894.
6. Tacket C.O., Sztein M.B., Losonsky G.A., Wassweman S.S., Natero J.P., Edelman R., Pickard D., Dougan G., Chatfield S.N., Levine M.M. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:1997;452-456.
7. Tacket C.O., Hone D.M., Losonsky G.A., Guers L., Edelman R., Levine M.M. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine. 10:1992;443-446.
8. Maniatis T., Fritsch E.F., Sambrook J. Nolan C. Molecular cloning: a laboratory manual. 1982;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
9. Miller J.H. Experiments in Molecular Genetics. 1972;Cold Spring Harbor Press, Cold Spring Harbor, New York.
10. Edwards M.F., Stocker B.A. Construction of delta aroA his delta pur strains of Salmonella typhi. J. Bacteriol. 170:1988;3991-3995.
11. Lengeler J. Streptozotocin, an antibiotic superior to penicillin in the selection of rare bacterial mutations. FEMS Microbiol. Lett. 5:1979;417-419.
12. Chatfield S.N., Fairweather N., Charles I., Pickard D., Levine M. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine. 10:1992;53-60.
13. Cryz J.S.J., Pasteris O., Varallyay S.J., Fürer E. Factors influencing the stability of live oral attenuated bacterial vaccines. Dev. Biol. Stand. 87:1996;277-281.
14. Westphal O., Jann K. Bacterial lipopolysaccharides; extraction with phenol-water and further applications of the procedure. Whistler R.L. Methods in carbohydrate chemistry. 1965;Academic Press, London.
15. Galanos C., Luderitz O., Westphal O. A new method for the extraction of R lipopolysaccharides. Eur. J. Biochem. 9:1969;245-249.
16. Galanos C., Lüderitz O. Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms. Eur. J. Biochem. 54:1975;603-610.
17. Brey R.N., Bixler G.S., Fulginiti J.P., Dilts D.A., Sabara M.I.J. Oral delivery of antigens in live bacterial vectors. Immunobiology of proteins and peptides. VI:1991;169-183.
18. Morrissey J.H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal. Biochem. 117:1981;307-310.
19. Leven J., Bang F.B. Clottable protein in Limulus: its localization and kinetics of its coagulation by endotoxin. Thromosis et Diathesis Haemorrhagiea. 19:1968;186-197.
20. Tartera C., Metcalf E.S. Osmolarity and growth phase overlap in regulation of Salmonella typhi adherence to and invasion of human intestinal cells. Infect. Immun. 61:1993;3084-3089.
21. Johnson K., Charles I., Dougan G., Pickard D., O'Gaora P., Costa G., Ali T., Miller I., Hormaeche C. The role of a stress-response protein in Salmonella typhimurium virulence. Mol. Microbiol. 5:1991;401-407.
22. Chatfield S.N., Strahan K., Pickard D., Charles I.G., Hormaeche C.E., Dougan G. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microbiol. Path. 12:1992;145-151.
23. Nisini R., Biselli R., Matricardi P.M., Fattorossi A., D'Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine. 11:1993;582-586.
24. Forrest B.D., LaBrooy J.T., Beyer L., Dearlove C.E., Shearman D.J. The human humoral immune response to Salmonella typhi Ty21a. J. Infect. Dis. 163:1991;336-345.
25. Gilman R.H., Hornick R.B., Woodward W.E., DuPont H.L., Snyder M.J., Levine M.M., Libonati J.P. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine. J. Infect. Dis. 136:1977;717-723.
26. Ivanoff B., Levine M.M., Lambert P.H. Vaccination against typhoid fever: present status. Bull. WHO. 72:1994;957-971.
27. Levine M.M., Ferreccio C., Black R.E., Tacket C.O., Germanier R. Progress in vaccines against typhoid fever. Rev. Infect. Dis. 11:1989;S552-S566.
28. Levine M.M., DuPont H.L., Hornick R.B., Snyder M.J., Woodward W., Gilman R.H., Libonati J.P. Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization. J. Infect. Dis. 133:1976;424-429.
29. Arricau N., Hermant D., Waxin H., Ecobichon C., Duffey P.S., Popoff M.Y. The RcsB-RcsB regulatory system of Salmonella typhi differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity. Mol. Microbiol. 29:1998;835-850.